CorMedix Inc. CRMD
5.56 USD +0.17 (+3.15%)
At closeNov 4, 2026, 4:00 AM EST
5.56 0.00 0.00%
Pre-market · Nov 4, 4:00 AM ET
5.30 Day range 5.60
5.30 52-week range 13.02
- YTD
- -52.19%
- 1 year
- -51.31%
- Market cap
- 433.37M
- Revenue (ttm)
- 12.26M
- EPS (ttm)
- 2.12
- Shares out
- 60.68M
- P/E ratio
- 2.62
- Forward P/E
- 17.54
- YTD return
- -52.19%
- 1-year return
- -51.31%
- Volume
- 2.46M
- Avg volume
- 1.27M
- Open
- 5.35
- Previous close
- 5.39
- Day's range
- 5.30 – 5.60
- 52-week range
- 5.30 – 13.02
- Beta
- 1.58
- Price target
- 16.25 (+192.3%)
30m -2.44 (-30.50%)
Key statistics
- Enterprise value
- 474.53M
- PEG ratio
- 0.00
- Price / sales
- 41.66
- Price / book
- 8.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -39.78M
- Total cash
- 46.03M
- Total debt
- 556.42K
- Return on equity
- -65.04%
- Short % of float
- 11.37%
- 50-day average
- 10.35
- 200-day average
- 6.57
Analyst view
Price target (mean) 16.25 +192.3% upside
Now 5.56
- Target (low)
- 11.00
- Target (mean)
- 16.25
- Target (high)
- 19.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy3
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.05.
Financials — quick view
CRMD Revenue — quarterly 101.93M
CRMD Net income — quarterly 25.99M
CRMD EPS — quarterly 0.33
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2025 | Sep 1, 2025 | 0.48 | 0.57 | +0.09 | +18.75% |
| Aug 7, 2025 | Jun 1, 2025 | 0.20 | 0.28 | +0.08 | +40.00% |
| May 6, 2025 | Mar 1, 2025 | 0.25 | 0.30 | +0.05 | +20.00% |
| Mar 25, 2025 | Dec 1, 2024 | 0.17 | 0.22 | +0.05 | +29.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 31, 2024 | Needham | main | Buy | Buy |
| Aug 15, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 15, 2024 | Needham | reit | Buy | Buy |
| Jul 25, 2024 | Truist Securities | main | Buy | Buy |
| Jun 19, 2024 | Needham | reit | Buy | Buy |
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cormedix.com
News
Needham Maintains Buy on Cormedix, Lowers Price Target to $12 
CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4 
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position 
CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027 - Actinium Pharmaceuticals Appoints Dr. Matt David As CFO
Your note
Sign in to keep a note on CRMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COSTA PAULO F | Director | Purchase | May 16, 2023 | 10,000 |
| DAVID MATTHEW T M.D. | Chief Financial Officer | Stock Award(Grant) | Jan 11, 2024 | 47,934 |
| DUNTON ALAN WILLIAM | Director | Purchase | Dec 14, 2023 | 15,250 |
| KAPLAN MYRON | Director | Purchase | May 17, 2023 | 196,034 |
| LEFKOWITZ STEVEN W | Director | Conversion of Exercise of derivative security | Nov 15, 2023 | 107,650 |
| MASSON ELIZABETH | Officer | Stock Award(Grant) | Jan 11, 2024 | 45,397 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.03% | 3,656,294 | 30.79M | Sep 29, 2024 |
| Vanguard Group Inc | 5.06% | 3,068,677 | 25.84M | Sep 29, 2024 |
| Elliott Investment Management L.p. | 2.56% | 1,550,523 | 13.06M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 2.43% | 1,475,000 | 12.42M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.12% | 1,284,464 | 10.82M | Sep 29, 2024 |
| State Street Corporation | 2.02% | 1,225,756 | 10.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.85% | 1,731,556 | 14.58M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.31% | 1,403,936 | 11.82M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 809,912 | 6.82M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.93% | 566,545 | 4.77M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.74% | 447,453 | 3.77M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 302,395 | 2.55M | Oct 30, 2024 |